

---

# Faculty and Disclosure Information for “Rheumatoid Arthritis Consult Collection”

---

## TARGET AUDIENCE

This activity is developed for rheumatologists.

## STATEMENT OF NEED

Rheumatoid arthritis (RA) is the most frequent form of inflammatory arthritis, affecting more than 2 million individuals in the United States. It is an autoimmune disease characterized by a persistent immunologic-mediated inflammatory reaction primarily affecting the synovial lining of the joints. The disease is most prevalent between the ages of 30 and 60 years, and affects women two to three times more often than it does men.

## LEARNING OBJECTIVES

Upon completion of this activity, participants should be better able to:

1. Determine appropriate assessment criteria and measurements for physiologic changes in joint and cartilage in order to accurately address the pathophysiology of the condition.
2. Examine the new class of selective T-cell costimulation modulators.
3. Determine the most appropriate patient profile for DMARD therapy to develop an RA program that will best serve the needs of the individual patient.

## FACULTY

**Arthur Kavanaugh, MD**, is professor of medicine, University of California, San Diego. **Joseph Markenson, MD**, is professor of clinical medicine, Weill Medical College of Cornell University, Attending Physician, Hospital for Special Surgery, both in New York, NY. **Chaim Putterman, MD**, is chief, Division of Rheumatology, associate professor of medicine and microbiology & immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY. **Terence Starz, MD**, is clinical professor of medicine, Division of Rheumatology, University of Pittsburgh School of Medicine, Pa. **Vibeke Strand, MD**, is adjunct clinical professor, Division of Immunology/Rheumatology, Stanford University, Palo Alto, Calif.

## ACCREDITATION AND CERTIFICATION

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Quadrant Medical Education. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center designates this educational activity for a maximum of *2 AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Statements of credit will be provided by mail following activity participation and upon completion and return of evaluation form to the Annenberg Center for Health Sciences at Eisenhower (#4562), 39000 Bob Hope Drive, Rancho Mirage, CA 92270 or by FAX to 760-773-4550. Please allow 4-6 weeks for the delivery of your statement.

## DISCLOSURE INFORMATION

It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any significant relationship with those supporting the activity of any others whose products or services are discussed.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center policy, the following disclosures have been made:

Dr. Kavanaugh reports he has received grant/research support from Abbott Laboratories; Amgen USA Inc; Biogen Idec; Bristol-Myers Squibb Company; Centocor, Inc; and Genentech, Inc. Dr. Markenson reports he has received grant/research support, is on the speakers' bureaus of, and is a consultant to the following: Abbott Laboratories; Amgen USA Inc; Bristol-Myers Squibb Company; Genentech, Inc; and Wyeth Pharmaceuticals. Dr. Putterman reports he has received grant/research support from Biogen Idec and is on the speakers' bureau of Bristol-Myers Squibb Company. Dr. Starz reports no conflict of interest. Dr. Strand reports she is a consultant to Abbott Immunology, Amgen USA Inc, Astellas, AstraZeneca, Bayhill, Biogen Idec, CanFite, Centocor, Chelsea, Cypress Biosciences, Inc, Dianippon Sumitomo, Genelabs, Genentech, Human Genome Sciences, Novartis, Omeros, Pfizer, Pharmacoepia, Propius, Rigol, Roche, Sanofi-Aventis, Schering Plough, Serono, SKK, UCB, Wyeth Ayerst, and Xdx; she is on the advisory boards of Abbott Laboratories, Amgen USA Inc, Biogen Idec, BMS, CanFite, Centocor, Chelsea, Novartis, Roche, Pfizer, Schering-Plough, and UCB; and is on the speakers' bureaus of Abbott Laboratories, Amgen USA Inc, Centocor, and Pfizer Inc.

The faculty for this activity have disclosed that there will be a discussion about the use of products for non-FDA approved indications.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage the practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account the patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

This activity is an enduring material and consists of a journal supplement. Successful completion is achieved by reading the material, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete this activity is 2 hours.

This activity was originally released in March 2007 and is eligible for credit through March 2008.

This activity is supported by an educational grant from Bristol-Myers Squibb.

---